EID Parry (India) Limited eid parry reported a robust start to FY27 with sugar segment revenue rising 18% year-on-year to ₹410 crore for the quarter ended June 30, 2026. The growth was primarily volume-driven, as the company sold 0.89 lakh metric tons (LMT) of sugar compared to 0.56 LMT in the corresponding quarter last year. This performance came despite operating its Tamil Nadu units for only 54 days against 37 days in Q1FY26 and crushing 1.47 LMT of cane versus 2.12 LMT previously.

The consumer product group (CPG) faced significant headwinds, with turnover falling nearly 50% to ₹94 crore from ₹188 crore in Q1FY26. CEO Muthiah Murugappan described this decline as an intentional recalibration of the business model towards margin-accretive products. While revenues have compressed, management noted that the absolute contribution margin pool has grown. The company targets achieving quarterly breakeven for the CPG division within the next four to five quarters.

Segment Performance

The nutraceuticals segment emerged as a key growth driver, with consolidated turnover more than doubling to ₹61 crore from ₹27 crore. CEO Murugappan attributed this surge largely to the US-based Valensa business, citing new product launches in derm health and hair care. He projected that steady-state EBITDA margins for the nutraceuticals division could reach between 12% and 15% once scale normalizes.

In the power segment, revenue dipped slightly to ₹6.6 crore from ₹7.53 crore. However, average power tariff realization improved significantly to ₹4.89 per unit from ₹3.67 per unit. Power exports fell to 89 lakh units (LU) from 122 LU, reflecting lower generation of 180 LU against 221 LU in the prior year.

What the Numbers Show

A critical divergence exists between the company’s operational scale and its revenue realization in the sugar business. While cane crushing volumes dropped 31% (from 2.12 LMT to 1.47 LMT) due to fewer operating days, sales volumes surged 59%. This indicates a deliberate drawdown of inventory, which stood at 1.1 LMT valued at approximately ₹42 per kg, down from 1.2 LMT in the previous quarter. This inventory management strategy allowed the company to capitalize on rising domestic sugar prices, which moved north of ₹45-₹46 per kg, offsetting the lower production base.

Balance Sheet and Subsidiary Restructuring

Management provided clarity on the financial restructuring of its subsidiary, PSRIPL. The parent company infused a total of ₹665 crore during the quarter to settle all bank liabilities, comprising ₹610 crore in equity infusion and ₹55 crore in loans. CFO Venkateshwarlu Y clarified that while ₹610 crore was recorded as impairment and ₹591 crore as reversal of financial liabilities, the actual cash outgo was ₹665 crore.

As of June 30, 2026, EID Parry’s standalone debt stood at approximately ₹1,130 crore, comprising ₹980 crore in short-term debt and ₹150 crore in long-term debt. Management emphasized a focus on working capital efficiency and monetizing non-performing assets, such as land parcels, to reduce debt levels further by March 2027.

Operational Challenges and Outlook

Feedstock availability remains a concern in Tamil Nadu and Andhra Pradesh, with farmers shifting to more lucrative crops like paddy. Chief Operating Officer Abdul Hakeem Ashiq noted that crushing in these geographies might see a flat or 5% decline in the current season. However, the company expects potential upside from Karnataka, contingent on favorable monsoon conditions in August and September.

Regarding ethanol production, management stated that high sugar prices currently make sugar production more economically viable than ethanol conversion. However, committed volumes to Oil Marketing Companies (OMCs) must be met to avoid penalties. The company plans to leverage its grain-based ethanol capacity (120 KLPD out of total 582 KLPD) to manage this trade-off.

EID Parry outlined its near-term operational roadmap during a recent conference call, highlighting a significant capacity expansion in its sugar division. The company plans to commission a new jaggery plant in Karnataka within six months. This facility is expected to more than double the current production capacity, contributing to a combined jaggery turnover closer to ₹100 crore from both existing and new plants.

Segment Outlook

The management provided specific guidance for its diversified business units, focusing on margin improvement and revenue growth across key segments.

Nutraceuticals The nutraceuticals segment is projected to deliver its highest-ever revenue this fiscal year. Management targets steady-state EBITDA margins between 12% and 15%, driven by increased scale and healthy operating performance.

Consumer Product Group (CPG) The CPG business is undergoing a turnaround phase. Management expects the segment to achieve quarterly breakeven within the next four to five quarters. While revenue is anticipated to remain lower, the company projects materially lower losses and improved margins compared to previous periods.

Financial Strategy for FY27

Looking ahead to March 2027, EID Parry has identified several key financial performance indicators to guide its capital allocation and operational efficiency. The strategy focuses on:

• Efficient working capital management
• Leveraging debt costs
• Monetizing non-performing assets
• Improving current ratios
• Implementing operational efficiencies and cost reduction programs

What the Numbers Show

The guidance reveals a strategic pivot towards high-margin, scalable operations while managing legacy losses. The target of ₹100 crore in jaggery turnover, achieved by more than doubling capacity, suggests a focus on volume-driven revenue growth in this niche segment. Simultaneously, the expectation of "highest-ever revenue" in nutraceuticals alongside a defined 12%-15% EBITDA margin band indicates that the company is prioritizing profitability over pure top-line expansion in its specialty chemicals arm. The CPG segment’s path to breakeven in four to five quarters implies a controlled deleveraging of losses rather than an immediate return to profit, balancing short-term pain with long-term structural improvement.